Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Aug 31;9(1):77.
doi: 10.1186/s13073-017-0470-9.

Clinical implications of neoepitope landscapes for adult and pediatric cancers

Yang-Yang Feng  1 , Obi L Griffith  2   3   4   5 , Malachi Griffith  6   7   8   9
Affiliations
Comment

Clinical implications of neoepitope landscapes for adult and pediatric cancers

Yang-Yang Feng et al. Genome Med. .

Abstract

Many immunotherapies rely on the presence of neoepitopes derived from somatic mutations that lead to altered peptide sequences. Several studies have now analyzed the neoepitope landscape of different cancer subtypes, predominantly for adult samples, which tend to feature significantly higher mutational burden. However, a new report publishing the first comprehensive analysis of the pediatric neoepitope landscape suggests that immunotherapies could also hold promise for pediatric cancers.See related research article 10.1186/s13073-017-0468-3.

Keywords: Exome sequencing; Immunotherapy; Neoepitope; Personalized cancer vaccine; RNA sequencing; Whole-genome sequencing.

PubMed Disclaimer

Conflict of interest statement

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Five-year relative survival versus neoepitope load in pediatric and adult cancers. Five-year relative survival is plotted against average neoepitope load for 29 cancer subtypes. Dot size represents the number of therapies approved by the US Food and Drug Administration (range 1 to 67) that are indicated for each specific disease. Survival data were obtained from the SEER Cancer Statistics Database (https://seer.cancer.gov), and drug counts for each cancer type were obtained from the A to Z List of Cancer Drugs provided by the National Cancer Institute (https://www.cancer.gov). Neoepitope load numbers are derived from the analyses presented in Chang et al. [7] and Charoentong et al. [8] for children (blue) and adults (red), respectively. *Neoepitope loads represent peptide–HLA binding predictions for missense single-nucleotide variants (SNVs) only. **Drug counts and survival rates for certain displayed subtypes are approximations as the NCI and SEER have grouped cancers differently compared with the sources of neoepitope load data. Abbreviations: ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, BLCA bladder urothelial carcinoma, BRCA breast invasive carcinoma, CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, CRC colon-rectum adenocarcinoma, EPD/CPC ependymomas and choroid plexus tumor, EWS Ewing sarcoma, GBM glioblastoma multiforme, HGG high-grade glioma, HNSC head and neck squamous cell carcinoma, KRP kidney and renal pelvis tumors, LGG low-grade glioma, LIHC liver hepatocellular carcinoma, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, MB medulloblastoma, MEL melanoma, NBL neuroblastoma, OS osteosarcoma, OV ovarian serous cystadenocarcinoma, PAAD pancreatic adenocarcinoma, PRAD prostate adenocarcinoma, RB retinoblastoma, RHB rhabdomyosarcoma, SKCM skin cutaneous melanoma, STAD stomach adenocarcinoma, THCA thyroid carcinoma, UCEC uterine corpus endometrial carcinoma
See this image and copyright information in PMC

Comment on

  • The neoepitope landscape in pediatric cancers.
    Chang TC, Carter RA, Li Y, Li Y, Wang H, Edmonson MN, Chen X, Arnold P, Geiger TL, Wu G, Peng J, Dyer M, Downing JR, Green DR, Thomas PG, Zhang J. Chang TC, et al. Genome Med. 2017 Aug 31;9(1):78. doi: 10.1186/s13073-017-0468-3. Genome Med. 2017. PMID: 28854978 Free PMC article.

References

    1. Liu XS, Mardis ER. Applications of immunogenomics to Cancer. Cell. 2017;168:600–12. doi: 10.1016/j.cell.2017.01.014. - DOI - PMC - PubMed
    1. Mardis ER. Neoantigen discovery in human cancers. Cancer J. 2017;23:97–101. doi: 10.1097/PPO.0000000000000248. - DOI - PubMed
    1. Meydan C, Otu HH, Sezerman OU. Prediction of peptides binding to MHC class I and II alleles by temporal motif mining. BMC Bioinformatics. 2013;14(Suppl 2):S13. doi: 10.1186/1471-2105-14-S2-S13. - DOI - PMC - PubMed
    1. Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014;24:743–50. doi: 10.1101/gr.165985.113. - DOI - PMC - PubMed
    1. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–13. doi: 10.1126/science.aan6733. - DOI - PMC - PubMed

LinkOut - more resources